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 Kava (Piper methysticum) is a traditional and culturally significant Pacific Island beverage 
that produces a soporific relaxant effect. Kava’s psychopharmacological action is similar to the 
anti-anxiety drug Benzodiazepine. Traditional users often consume the kava drink at volumes as 
much as 30 times greater than pharmacologically recommended doses. Prompted by concerns 
regarding driver impairment post kava drinking, a study was undertaken replicating traditional 
kava sessions in terms of duration and kava consumption, to investigate the effects of kava on 
driving capability.  
 
Kava consumers (n=20) attended two six-hour kava sessions, each participant drinking an 
average 3.52 litres of kava. A non-kava consuming control group (n=20) was included in the 
study. At baseline all the participants completed computerised industry standard driver safety 
assessment tests (Vienna Test System: Traffic WAFA Alertness and WAFG Divided Attention) to 
measure reaction time, perception and attention.  Re-testing was conducted at hourly intervals 
over the six-hour period. Pre/post analysis compared person to person and between groups 
change.  Statistical modeling was based on ANOVA, independent t-tests and Bayesian analysis.   
 
Data analysis indicated no statistically significant (p<0.05) difference between reaction 
time and divided attention, both within individuals and between groups, at any measurement 
point over the six-hour testing period. The mean reaction time and divided attention time at the 
baseline measurement was 249.95msec (milliseconds) and 583.58msec respectively.  The 
control and active group mean reaction time at the final test was 256.70msec and 271.8msec 
respectively. The mean divided attention times for the control and active groups at the final test 
were 499.75msec and 568.32msec. 
 
Kava at traditional consumption volumes was not correlated to response latency or 
impairment on perception and attention tasks, when measured using authoritative driver 
assessment tests. From this it could be inferred that kava use at traditionally influenced 




current industry standard accepted cognitive measures of driver safety, assess impairment from 
the use of euphoric and hallucinogenic drug substances (such as alcohol and marijuana), and fail 
to account for kava’s unique form of ‘intoxication’. Further research beyond the assessment of 
these two cognitive functions is, it seems, desirable to better understand if kava has any effect 
on driver ability.   
 
The study was funded by the Health Research Council of New Zealand (16/462) and the 
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Kava drinking has been central to the traditional practices of Pacific Island peoples for 
more than two thousand years. More recently, kava consumption has moved from the Pacific 
Islands to New Zealand (NZ), Australia, Canada, the USA and Europe as the Pacific diaspora has 
spread across the world. This has in turn influenced kava use by non-Pacific Islanders who, in 
some cases, reflect traditional use, consuming volumes as high as 30 times the 
pharmacologically recommended daily dose. Increased kava consumption has also led to an 
increase in driving to and from kava venues, with the police in NZ and the Pacific reporting rising 
numbers of suspected kava ‘intoxicated’ drivers. This report documents a study that measured 
impairment during and following the consumption of kava with the aim of understanding driver 
ability to improve road safety.     
 
2 Background 
Piper methysticum, or the kava plant (Figure 1), is believed to have originated in 
Northern Vanuatu (Lebot et al., 1992) and was subsequently transported throughout Eastern 
Pacific Oceania and areas of Western Pacific Oceania by early voyagers and traders from 
approximately 3000 years ago (Crowley,  1994; Kirsh & Green, 2001). The crushed root and basal 
stump of the kava plant are steeped in water to make a traditional drink (Figure 2). It should be 
noted that the kava plant and drink are culturally significant to many Pacific people, being 
consumed at almost every major event from birth to death (Aporosa, 2014b).  In Fiji and Eastern 
Pacific Oceania (Polynesia), kava drink is frequently used to facilitate talanoa (culturally guided 
discussion) at kalapu’s (traditionally influenced kava drinking venues1), where drinkers sit cross-
legged on woven mats with the kava served from a centrally located kumete (wooden kava 
bowl) (Figure 3). The average duration for a Fijian, or Polynesian kava session, is approximately 
six hours, in which drinkers can consume up to 3.6 litres (6.33 pints) (Aporosa, 2014b). 
 
 
                                                          
1
 Kalapu is a Tongan word literally meaning ‘club’. Kalapu is increasingly being adopted (particularly in NZ) by 




Figure 1: Piper methysticum (kava), approximately 3 years of age. 
                                            
 
 







(Aporosa, 2008, p.21).                                                           (Singh, 2004b, p.61). 
 
Figure 2: Contemporary mixing of kava: The ground kava roots (and/or basal stump) in a silk bag  









(Payson, 2008, p.127) 
 













Kava as a drink was relatively unknown outside of the Pacific Islands and diasporic Pacific 
communities until the early 2000s, when a report in Europe claimed 83 patients taking 
pharmaceutically manufactured kava tablets had died from hepatotoxicity or liver damage 
(Schmidt et al., 2005; Showman et al., 2015).  This led to what is commonly known as the 
‘European Kava Ban’, and the withdrawal of kava from European markets. This had the effect of 
raising the profile of kava to the point where it was mentioned in medical and media reports, 
linking aqueous kava with hepatotoxicity.   
 
In 2014, following a 12-year court battle, the kava ‘ban’ was overturned by the Federal 
Court of Germany. The Court ruled that it was unlikely kava had caused the reported deaths, 
and that liver damage from kava was so rare it was negligible. The Court added that claims of 
kava being responsible for liver related deaths was a misrepresentation of the possible effects 
(Schmidt, 2014).  The 2016 World Health Organisation’s (WHO) kava risk assessment report 
states: “On balance, the weight-of-evidence from both a long history of use of kava beverage 
and from the more recent research findings indicates that it is possible for kava beverage to be 
consumed with an acceptably low level of health risk." (Abbott, p.26; also see Teschke, 2010)  
Although the reputation of kava is slowly recovering, the belief that kava damages the liver 
remains, a myth that continues to be perpetuated in some authoritative publications (for 
instance, see Graziano et al., 2017, p.754; Procyshyn et al., 2017, p.390).  Other kava myths 
include hallucinogenic effects, and that it is addictive and causes a damaging skin condition. (For 
more on these misunderstanding and other kava myths, please see Aporosa, 2016). 
 
Kava contains a number of active compounds called kavalactones, of which six are 
reported as being responsible for its psychoactive affect (Lebot & Levesque, 1996; Dragull et al., 
2006).  Kavalactones have each been allocated a number to aid chemotype classification.  The 
following kavalactones are prefaced with their chemotype number and followed with their 
abbreviation: 1. demethoxy-yangonin (DMY); 2. dihydro kavain (DHK); 3. yangonin (YAN); 4. 
kavain (KAV); 5. dihydromethysticin (DHM); and, 6. methysticin (METH) (see Figure 4).  




neurotransmitter release excitation, and the potentiation of GABAA through enhanced ligand 
binding to the GABA (gamma-Aminobutyric acid) receptors. This creates a reduction in the 
neuronal re-uptake of noradrenaline responders and possibly dopamine, leading to a reversal of 
monoamine oxidase (MAO) B inhibition (Ligresti et al., 2012; Lim, 2016). Although this 
explanation implies a high level of knowledge regarding kavalactone psychopharmacology, 
Bwarenaba and colleagues (2017) warn that kavalactone “modes of action are not fully 
understood” (p.1), with even less known about “the neurophysiological mechanisms associated 
with kavalactone metabolism” (p.5).  Additionally, the WHO also admit to large knowledge gaps 
concerning kava ethnobotany and psychopharmacology, and have requested research on these 
factors related to “human health effects” (Abbott, 2016, p.viii).   
 
Figure 4: Chemical structure of the six major kavalactones present in kava beverage made from 












(Dragull et al., 2006, p.21). 
 
Kava users describe kava as producing a subtle sense of relaxation and sociability without 
impairing judgment or causing disinhibition, as experienced with alcohol (Aporosa & Tomlinson, 
2014).  Kava is neither alcoholic nor hallucinogenic, and its effects are different to those of 




a unique experience, one which is frequently criticized by new users who report, “they don't feel 
a thing” (Thomson, 1999, p.72).   
 
Kavalactones within the plant and drink are responsible for kava’s use in traditional 
medicine (Lebot & Cabalion, 1988).  This includes anti-stress inhibitors recognized by Western 
pharmacology. This has led to kava being prescribed (ME, 2017) as a non-addictive anxiolytic 
alternative to Benzodiazepine, in the treatment of Generalised Anxiety Disorder (GAD) (Sarris et 
al., 2013; Lim, 2016). Kava prescribed for GAD is typically administered in tablet (and 
occasionally syrup extract) form, and restricted to no more than 300mgs of kavalactones per 
day. This complies with pharmacological guidelines (MediHerb, 1994), providing therapeutic 
value without causing cognitive impairment (Mills & Bone, 2005).  
 
Kava’s anti-anxiety affect, together with its attraction as an alcohol alternative and ‘social 
lubricant’, has led to its use by an increasing number of non-Pacific ethnicities, some of whom 
also engage in lengthy traditional-style kava sessions consuming quantities similar to Pacific 
peoples (Aporosa, 2015; Showman et al., 2015; Wolinski, 2018) (see Figure 5). However, unlike 
prescribed kava tablets, kavalactone quantities ingested during ‘average’ drinking sessions in Fiji, 
often equate to more than 8,000mg of kavalactones, or 30 times the pharmacologically 
recommended daily dose (Aporosa, 2008; Aporosa & Tomlinson, 2014; Showman et al., 2015). 
 






LaPorte and his team (2011) were the first to complete a systematic review to assess the 
effect of kava on cognition.  In most of the studies they reviewed, participants received between 
200 – 300mg (tablet doses) of kavalactones per day.  LaPorte et al. (2011) state that due to 
inconsistent “study designs and use of control” (p.108), it was difficult to establish the 
psychopharmacological effect of kava. For instance, in one of the studies they reviewed, it was 
suggested that acute kava use increased body sway and significantly impaired visual attention, 
whereas in another study it was reported that: “kava significantly enhanced visual attention and 
working memory” (p.110).  They concluded: “kava has non-deleterious effects on cognition 
during acute administration or produces reduced visual attention at higher doses during 
cognitive demand.” (p.110) However, while LaPorte and colleagues cautioned that until “a more 
detailed account of the risk benefit ratio of kava on cognition” has been established, “caution is 
advised when driving and operating heavy machinery” (p.110).   
 
In a recent study from New Zealand (NZ), 20% of drivers reported taking drugs known to 
interfere with their driver safety within three hours of driving (Starkey et al., 2016).  Drug and 
alcohol-driving prevalence in NZ is a significant health and safety issue and is estimated to have 
an annual ‘social cost’ of $564m (MoT, 2017, p.4).  Injury resulting from road traffic accidents is 
the leading cause of hospitalisation for Pacific men and women (Slack et al., 2009).  
Hospitalisation as a result of drug use among Pacific peoples is also higher than the general 
population, and increases significantly with age (Slack et al., 2009).  Research focused on Tongan 
kava drinkers, report that it is common for 70% to drive home from kava drinking sites (Maneze 
et al., 2008), travel that can include inter-city driving (Aporosa, 2018).   
 
Over the past five years the NZ police have reported increased numbers of kava 
'intoxicated' drivers (Morgan, 2014, 2017; Welsh, 2016).  Further, the New Zealand Institute of 
Environmental Science and Research (NZESR) reports the increased presence of kavalactones in 
the blood of deceased motor vehicle accident victims (Poulsen et al., 2012).  By combining 
statistics on kava use from the NZ Alcohol and Drug Use Survey with two ethnographic studies, it 




kava drinking sessions on an average Friday or Saturday night in NZ (Aporosa, 2015).  It is 
presumed that the high Pacific hospitalisation rates resulting from road traffic accidents and 
drug use, have an as-yet unrecognised link with kava use and driving.  This potentially puts a 
large number of Pacific peoples and other road users at high risk of injury.  
 
To date, there has only been one successful kava-driving prosecution in NZ (DCNZ, 2000), 
and a small number overseas (Swenson, 1996; Jolly, 2009).  While this subject is of concern to 
road safety commentators and law enforcement agencies (Morgan, 2014, 2017; Wainiqolo et 
al., 2015; Welsh, 2016), the reality is that very little is known about the effects of kava at 
traditionally consumed volumes, on cognitive faculties related to driver safety.  Additionally, 
when LaPorte et al.’s (2011) limited understanding regarding kava cognition is added to 
Bwarenaba and colleagues (2017) concerns about kava psychopharmacology and 
neurophysiology, this points to the urgency to undertake research in this field. 
 
2.1 Research Aim  
This study, the first of its kind, aims to measure reaction time and divided attention 
during and immediately following traditionally influenced kava consumption, and apply the 
results to safe driver functionality, to better understand kava related cognition, driver safety and 
coordination. It is anticipated this information will improve road safety, reduce injury and 
hospitalisation, and the related economic and social costs, to positively impact on the health of 
Pacific peoples and other road users both in NZ and internationally. 
 
2.2 Hypothesis  
Kava consumers (active group) show changes in (1) reaction time and (2) divided 
attention compared with the control group.    
 
3 Methodology 
 This study was based at the University of Waikato’s Anthropology Programme and 




study was granted by the University of Waikato’s Human Research Ethics Committee (HREC 
[Health] #34).  
  
This study is aimed at measuring the cognitive effects during and following the ingestion 
of high volumes of kava as consumed in traditional settings.  Underpinning the methodology is 
the Post-Development Pasifika methodological framework, developed by Aporosa (2014a). The 
framework is guided by Fijian cultural respect based values and appropriate practice which can 
be applied across Polynesia.  Additionally, the framework encourages and endorses naturalized 
research settings as sites of participant engagement.   
 
The number of participants necessary to achieve statistical significance was influenced 
by McCready (1996). McCready suggests that in experimental projects that involve 
psychometric testing, studies with a similar research focus should be used to guide sample sizes. 
Nine studies that measured cognition in kava users following minute pharmacologically 
recommended doses were consulted (Mathews, et al., 1988; Russell et al., 1987; Saletu et al., 
1989; Münte et al., 1993; Prescott et al., 1993; Heinze et al., 1994; Schelosky et al., 1995; Foo & 
Lemon, 1997; Spillane et al., 1997).  Heinze et al.’s 1994 study, was identified as the most 
influential, as it measured effects similar to the aims of this study i.e. driver ability. The Heinze 
research utilised twelve participants and provided statistically robust effect measured data.  
This present study chose to more than double this number. 
 
3.1 Participants 
Thirty kava using participants, who will be referred to as the ‘active’ group, were 
recruited from kalapu’s in Hamilton and Auckland. An additional thirty non-kava drinking 
participants, referred to as the ‘control’ group, were recruited by word of mouth and through 







3.1.1 Participant eligibility 
The initial recruitment criteria were for participants to be over 18 years of age, and who 
held a full (unrestricted) driver’s licence.  This was followed by completion of an eligibility 
screening form. This was aimed at ensuring that all participants were in good health and an 
absence of neurological or psychological conditions such as previous head injury, concussion or 
psychotic disorders.  On the eligibly screening form, participants were asked a range of simple 
questions related to the health matters above, and asked to tick either ‘yes’ or ‘no’.  Participants 
were also screened for anxiolytic or sleep medication use.    
 
Active participants were also questioned about their kava use.  This allowed novice kava 
users to be identified and weeded out, as the study required those who could demonstrate 
regular use of kava at high consumption volumes over multiple hours.  Following selection for 
participation, the active participants were requested not to consume any kava over the four 
days prior to testing.  Drawing on in vivo experiments with mice and rats, Singh (2004c) states 
that kava has a drug half-life of nine hours.  This suggests it takes as many as 90 hours, or almost 
four days, for kava to be eliminated from the body (Aporosa, 2008).  The use of ‘suggests’ is 
deliberate due to Bwarenaba et al.’s (2017) observations regarding limited kava 
psychopharmacology.  Due to the increasing use of kava by non-Pacific peoples, ‘other’ 
ethnicities in addition to Pacific Islanders were also recruited, and included, in both the active 
and control groups.  
 
Eligibility screening of control participants also sought information on whether they had 
ever consumed kava, and if so, how recently. In a few cases, where control participants had 
consumed kava within six months of testing, they were made ineligible for inclusion in the study 
to ensure all control participants were kava free. Nine of the 20 control participants 
acknowledged previous kava use, most commonly as part of either a cultural experience at the 
University of Waikato or whilst on holiday in Fiji. However, none of them had consumed kava 





Individuals who met test eligibility following screening were given an information sheet 
explaining the research aims, procedures, expected time commitment and requirement not to 
consume alcohol within 24 hours prior to testing.  The control participants were also reminded 
that they must remain kava free to be eligible for testing, whereas the active participants were 
advised to cease kava use four days out from testing.  One week prior to testing, the computer 
and test software were given dry-run, in the presence of an Information Technology specialist.   
 
3.1.2 Participant demographics 
Sixty-seven participants were initially screened for recruitment with seven subsequently 
not meeting the criteria. This provided three groups of twenty participants with each group 
comprising ten active kava drinkers and ten control non-drinkers.  Shortly after the start of the 
first test session there was a mass computer failure, which led to the elimination of group one 
from the study.  Of the remaining 40 participants who progressed to full testing, their average 
age was 35.2 years old (SD = 9.8).  Average age for those in the ‘active’ groups was 35.3 years 
(SD = 9.5) and control 35.1 years (SD = 10.4). Participants were mostly male with the exception 
of two females in both the ‘active’ and ‘control’ groups. 
 
The ethnic make-up of the 40 participants were: twelve Māori (indigenous New 
Zealanders), who accounted for the largest ethnic representation of which four were active 
participants; six each identified as Tongan and Fijian, of which all were active participants; five 
New Zealand Europeans (one of whom was active); four Samoan’s (one being active); two Papua 
New Guineans (both control); one each of Rarotongan, Indian, Hawaiian and Afrikan descent, all 
of whom were control participants; and, one Amer-Indian who was an active participant.  
 
Thirty-six of the participants were male. There were two Tongan females who were 







 3.1.3 Research participant test preparation 
On each of the three testing days, research assistants transported the participants from 
their homes in vans to a lecture room (see Figure 6) adjacent to a psychology computer lab at 
the University of Waikato.  The participants arrived at 6pm allowing time to be briefed on the 
study procedures and sign informed consents.  It was made clear to all the participants that 
should they wish to withdraw from the study, they were free to do so at any time and a taxi 
would be ordered to transport them home. No participants withdrew from the study. 
 
Active participants were also reminded that they would be served kava at precise 
intervals six times per hour for six hours, and that at each serving they were free to choose their 
serve quantity which ranged from decline to 25mls (milliliters), 50mls, 57mls and 100mls 
(equivalent to 0.2 pints) (see measuring tubes on top rim of kumete in Figure 6).  The 
participants were advised that their kava intake would be recorded by one of the two research 
assistants aiding the chief investigator. In addition to this, research assistants were also asked to 
make notes of any unusual behavior amongst the participants, as the test event proceeded.  The 
participants were also reminded that they would undergo computer-based psychometric testing 
in the adjacent computer lab on the hour over the test period.  
 






All research participants were invited to partake of snack foods and non-alcoholic drinks 
at their leisure during the test period. These consisted of typical kava chasers, or food items 
consumed during a regular kava session. These included salted potatoes chips and peanuts, 
apples and pears, and lollipops (a boiled sweet on the end of a stick).  Drinks consisted of water, 
sports rehydration drinks, lemonade and Coco-Cola.  Participants were asked not to consume 
energy drinks or caffeine.  Additionally, the participants were informed that they were free to 
move about and leave the lecture room to use the toilet, although the active group members 
were to be present in the lecture room at kava serving times, and all participants were to be 
available on the hour for testing in the computer lab.  Although the study adhered to some strict 
conditions (such as driver’s licence requirements, a health screening check, kava serving times 
and psychometric testing procedures), flexibility around kava serving portions, the consumption 
of chasers, and the freedom to move about was allowed so as to create a ‘naturalised’ setting of 
kava consumption. 
 
Two short videos explaining the psychometric tests were shown to the participants with 
time given for questions and answers. Once all the participants were familiar with the test 
procedures, they were taken a few metres away to an adjacent computer lab where they 
completed the first psychometric test session to provide baseline data.    
 
Following baseline testing, all of the participants were returned to the ‘kava room’ and 
invited to sit on woven mats where isevusevu was presented. This is a Fijian influenced cultural 
acknowledgement in which the participants were thanked for their time and participation.  All 
Pacific peoples have cultural practices similar to isevusevu, including Māori who call their 
equivalent pōwhiri or whakatau (Aporosa, 2017).  Additionally, this aided a ‘naturalised’ kava 
consumption setting, and complied with Pacific cultural expectations and obligations guided by 
Aporosa’s (2014a) Post-Development Pasifika methodological framework.  The control 
participants did not consume kava during the isevusevu or at any point during the testing phase.  




kava, as supplied relevant to their participation in the study, and occasionally left the room to 
use the toilet. 
 
3.2 Psychometric tests 
Two driver safety psychometric assessments were drawn from the Vienna Test System 
(VTS) test battery. VTS have been supporting traffic psychology research through the provision 
of industry standard assessment measures for more than 50 years.  All VTS assessments have 
been validated with more than 1,350 assessments being used at test centres worldwide (VTS, 
2016).   These tests are designed for multiple-use on single participants without compromising 
test-retest validity. Additionally, the tests are ethno-friendly and designed so as not to 
marginalize participants in the study, who may have English as their second language.   
 
Two specific VTS tests were chosen as these measured cognitive faculties critical to 
driver safety and could be completed within nine minutes; a time period that did not disrupt the 
kava serving time rate/pace. A total of seven test sessions were held per group (10 active and 10 
control), over the six hour test period, delivered in a University of Waikato School of Psychology 
computer lab (adjacent to the ‘kava room’) on a suite of Dell Optiplex (9020) desktop 
computers.  These tests were: 
 
3.2.1 The WAFA Alertness (intrinsic visual) test 
 The WAFA Alertness (intrinsic visual) test takes three minutes to complete and requires 
the participant to press a ‘green’ button (on the computer keyboard) as quickly as possible 
every time a large black circle is presented on the white computer monitor screen.  The WAFA 
test measured reaction and attention intensity (Sturm, 2011a).  In total, 50 stimuli were 
presented of which 25 were randomly selected for “mean reaction time” assessment 
(Aschenbrenner et al., 2012, p.9,15). 
 
3.2.2 The WAFG Divided Attention (uni-modal visual) test 
 The WAFG Divided Attention (uni-modal visual) test also took three minutes to 




on a white computer screen).  If one of the stimuli becomes lighter [in colour], twice in 
succession, the participant registers this change by pressing a ‘green’ button (on the computer 
keyboard) as quickly as possible (Sturm, 2011b).  The lights in the laboratory were dimmed to 
aid participants in recognizing stimuli colour-change. The WAFG test specifically measures 
parallel processing and selectivity of attention (Sturm, 2011b).  In total, 85 sets of stimuli were 
presented of which 21 were randomly selected for “Mean reaction time” assessment 
(Aschenbrenner et al., 2012, p.9,15).  
 
3.3 Kava preparation, cultural compliance and serving 
Dried powered kava root/basal stump, originating in Tonga, was purchased from a 
reputable and well-patronised retailer in Hamilton, New Zealand. A sufficient quantity of kava 
was purchased for all tests to aid standardization. Kava retained for later testing was 
compressed into heavy-duty plastic bags, and stored in an airtight container in a dry dark 
cupboard at approximately 18oC to maintain freshness (AECOM-Kalang, 2017).  Prior to each 
test session, 36 litres (9.51 gallons) of kava was mixed for consumption approximately one hour 
before the session. This used a standardized recipe with the kava concentration estimated to be 
similar to the average kava strengths in kalapu’s in New Zealand.  Additionally, the ‘recipe’ 
enabled easy duplication.   
 
A 200gm (7.05 ounce) sample of the dried kava powder, together with the recipe, was 
couriered to T.K Group Laboratories in Iowa, USA for kavalactone strength analysis. Kava residue 
from multiple samples that had been evaporated at 40ᵒC, were extracted for analysis. The kava 
was found to contain no adulterants, with a strength rating of 9.26% total kavalactones by dry 
weight, a chemotype of 423651, and a mean kavalactone content of 145mg per 100ml of kava 
beverage.  Certificates of analysis are attached at Appendix A. 
 
The kava was served from a kumete in bilo/ipu (cups made from coconut shells) using 
measured quantities (decline to 25mls (milliliters), 50mls, 57mls and 100mls) as directed by the 





3.4 Test conclusion 
The final testing was undertaken following the sixth hour of kava consumption.  The 
participants were acknowledged with tatau, similar to isevusevu, a Fijian influenced protocol 
thanking the participants for their time and participation. This also complies with Pacific cultural 
expectations, obligations, and the Post-Development methodological framework (Aporosa, 
2014a).  This provided an opportunity for some of the control participants to consume kava for 
the first time.  The tatau was followed by a substantial meal, and presentation of a $100 gift 
voucher to thank each of the participants for their time. All were provided with a ride home.  
The test session took approximately 7.5 hours to complete. 
 
3.5 Data analysis 
VTS test results were presented in numerical format and were easily imported to a 
variety of software options allowing data analysis. Pre/post data analysis was conducted 
comparing person to person and between groups change. Statistical modeling was based on 
ANOVA, independent t-tests and Bayesian inference.  Bayesian analysis produces a ‘Bayes 
factor’ which is used for comparative analysis. A Bayes factor is a ratio of the likelihood of a 
specified hypothesis (e.g. effect of a treatment) to a second hypothesis (e.g. no effect). 
 
4 Results and discussion 
4.1 Kava consumption volumes 
Only eight of the 20 active participants consumed the maximum average of 3.6 litres of 
kava over the six hour test period, drinking the full 100mls of kava at each serving.  At least half 
of the eight participants who consumed the maximum average – which included one of the 
female participants – complained that 100mls was less than they usually drank, and requested 
larger portions of kava.  This was declined.  In most cases the remaining 12 participants 
commenced the testing with smaller portions although by midway through the test session they 
increased their servings to consume the full 100mls at each serve.  When questioned at the 
conclusion of testing about this, most reported feeling a little under pressure at the start, 




progressed they felt more confident that they could finish the full test session and therefore 
changed to consume the standard average.  Over the full six hours of testing, the active 
participants consumed on average 3.0585lts (litres, or 6.117 pints) each (SD = 0.713 litres), of 
kava drink which can be calculated as up to 4,426.145mgs of kavalactones.  This is 
approximately 15 times greater than pharmacologically recommended dose.   
 
4.2 Psychometric tests 
 The mean reaction time and divided attention at baseline was 249.95msec (SD=37.57) 
and 583.58msec (SD=226k .62) respectively. 
 
4.2.1 The WAFA Alertness (intrinsic visual) test 
 Conflicting with the hypothesis, the data analysis of the WAFA Alertness test results 
indicated no statistically significant (p<0.05) difference in reaction time and attention intensity 
[F=(13,264), 0.582, p=0.868], both within person and between groups at any measurement 
point over the six-hour testing period (Figure’s 7).  Figure 7A shows the mean reaction and 
attention intensity time for the control participant groups, at hourly test intervals. After six 
hours, the mean reaction and attention intensity time was 256.70msec (SD=36.86); this being 
7msec (milliseconds) slower than baseline.  Similarly, Figure 7B shows the mean reaction and 
attention intensity time for the kava consuming active participant groups at hourly test 
intervals.  After six hours, the mean reaction and attention intensity time was 271.8msec 
(SD=46.32); this being 22.10msec slower than baseline.  The insignificance of this difference is 
demonstrated when compared to the effects of alcohol consumption on driver reaction time.  
Grant et al. (2000), showed that consuming 50µg (milligrams) of alcohol (equivalent to the 
current 0.05 NZ driver blood alcohol limit), slowed driver reaction time by 70msec, and this 
increased to 120msec at 0.08 (the previous limit).  Finally, Figure 7C shows the change in an 
individual’s mean reaction time from baseline correlated with volume of kava consumed.  





Bayesian inference analysis corroborated the ANOVA and independent t-tests analysis 
results.  This showed that at baseline the p-value (probability value) for all participants was 
0.280 and at the end of testing at hour six when the active and control participants were 
compared, 0.585.  Bayesian comparative analysis between baseline and final test at the sixth 
hour for the control participants was p=0.627 and for the active participants p=0.983. Bayesian 
comparative analysis between the control participants and the active participants at the sixth 
hour of testing yielded a Bayes factor of 0.472.  This Bayes factor suggests no meaningful 
difference between the active and control. 
 
4.2.2 The WAFG Divided Attention (uni-modal visual) test 
 Again conflicting with the hypothesis, data analysis of the WAFG Divided Attention 
results indicated no statistically significant (p<0.05) difference in parallel processing and 
selectivity of attention [F=(13,264), 0.834, p=0.624], either within person or between groups at 
any measurement point over the six-hour testing period (see Figure’s 8). Figure 8A shows the 
mean divided attention time for the control participant groups, at hourly test intervals. After six 
hours, the mean divided attention time was 499.75msec (SD=167.62), which is a small decrease 
(ie. improvement) of 83.83msec when compared with baseline. Similarly, Figure 8B shows the 
mean divided attention time for the kava consuming active participant groups at hourly test 
intervals. After six hours, the mean divided attention time for the active participant groups was 
568.32msec (SD=217.71), a, average decrease (ie. improvement), although only slightly by 
15.26mls. Figure 8C shows the change in an individual’s mean reaction time from baseline 
correlated with volume of kava consumed.  The positive values indicate slower reaction time 
and negative values faster. 
 
Bayesian inference analysis corroborated the ANOVA and independent t-tests analysis 
results.  This showed that at baseline the p-value for all participants was 0.385 and at the end of 
testing at hour six when the active and control participants were compared, 0.607.  Bayesian 




participants was p=0.965 and for the active participants p=0.783. Bayesian comparative analysis 
between the control participants and the active participants at the sixth hour of testing yielded 
Figure 7: WAFA Alertness (intrinsic visual) test results 
Figure 7A: Control participant hourly reaction time                                                                   
 
Figure 7B: Active participant hourly reaction time 
 





Figure 8: The WAFG Divided Attention (uni-modal visual) test results 
Figure 8A: Control participant hourly divided attention time                                                 
 
Figure 8B: Active participant hourly divided attention time 
 
Figure 8C: Change in individual mean divided attention time from baseline with kava consumption 
R2 = -0.02 













a Bayes factor of 0.492.  Again, this Bayes factor suggests no meaningful difference between the 
active and control and show no correlation between consuming kava at traditional volumes and 
response latency or impairment on divided attention tasks. 
 
4.3 Observations 
   At the conclusion of each test event, the chief investigator and research assistants 
discussed observations they had made regarding participant changes over the duration of the 
test period. The research team unanimously agreed that as the six hours progressed, subtle 
changes were observed in many of the kava drinkers, namely slowing psychomotor response, a 
somnolent-like state, altered word pronunciation and a slowing of speech rate. These 
observations align with reports from both NZ and Pacific based Police, who state that kava drink-
drivers observed during road-side stops, typically exhibit decelerated body movement and 




  Anomalies between police observations of kava drink-drivers at road stops and those of 
the research participants as observed during this study, led to lengthy discussions with experts 
such as; Professor Jerome Sarris, a specialist in psychopharmacology and cognitive function from 




neuropsychopharmacologist specialising in drug-brain interaction at the Imperial College 
London;  Associate Professor Brett Langley, a neuroscientist from the Harvard Medical School 
(now at the University of Waikato); and, Professor Nicola Starkey, a specialist in cognition, driver 
fitness and psychological assessment. These conversations were to consider possible 
explanations for the effects of kava including an analysis of the study structure, approach and 
methodology. 
 
 One aspect that was discussed was the possibility of participant interruption/disruption 
over the six-hour testing period.  During a typical kava session, drinkers sit for lengthy periods 
and engage talanoa. Discussions raised the possibility that excessive cognitive assessment may 
have influenced test results, as participants were required to leave the kava consumption 
environment each hour and move to the adjacent computer lab for testing.  It was suggested 
that in future, fewer tests would still provide adequate data points while having a lesser impact 
on the kava environment and participants. 
 
The effects of kava reverse tolerance was also discussed with the experts. Unlike many 
substances, kava users do not build tolerance (Singh, 2004a). Rather, users experience ‘reverse 
tolerance’, in which repeated use leads to greater effects. Although reverse tolerance has been 
suggested as a potential reason why kava does not cause physical addiction (Mindel, 1998; 
Steiner, 2001), the reality is that little is known about kava and this phenomenon. It was agreed 
this unknown was beyond the current study.  
  
  The team also discussed studies that had investigated the effects of Benzodiazepine on 
driving. Of interest to those deliberations was the work of Saletu and colleagues (1989). They 
discovered that although there are similarities in anxiolytic action between Clobazam (a type of 
benzodiazepine) and kava, EEG-brain mapping of participants taking kava reported a decrease in 
beta activity, whereas Clobazam greatly increased beta activity. Increased beta activity is 
associated with attention, alertness, problem solving, decision-making and judgment.  These 




medication.  Moreover, that difference potentially provides an explanation for the lack of impact 
by kava on attention and divided attention in the present study; an effect which stands in 
opposition to the actions of benzodiazepine on these same cognitive faculties. Additionally, 
Verster et al. (2004) state that although benzodiazepine medication reduces anxiety, there is 
variability in effect characteristics, drug half-life and dosages between benzodiazepine varieties, 
with resulting differences in cognitive impact on driving ability.  
 
In addition to Saletu et al. and Verster et al’s. work, the literature explaining kava’s action 
on GABAA, particularly the role kava plays in decreasing neurotransmitter function in the central 
nervous system (CNS), was considered (Ligresti et al., 2012; Lim, 2016). It was suggested that 
potentially the psychometric tests used in the current study lacked utility in kava cognition 
assessment, as they relied on visual-sensory as opposed to the CNS to measure impairment. It 
was further suggested that an alternative approach was required, one that could measure kava 
impairment via the CNS.  Moreover, the ability to measure subtle/slight change would be critical 
in light of Saletu and colleagues findings regarding kava’s action in increasing beta activity.   
 
A new testing system has subsequently been identified. This is a recently developed 
highly sensitive neuroscientific assessment tool (name deliberately withheld due to ongoing 
research), which measures slight changes in strategic, tactical and operational cognitive aspects 
including fine-motor-skills and fatigue. This assessment measure was recently pilot tested during 
a kava session of six hours (in which two participants consumed 3.6 litres of kava each and were 
tested at baseline, at the mid-point and again at conclusion). The pilot study results 
demonstrated the viability of undertaking a full-length study, which is planned for 2019. 
 
The findings from the present study were discussed with staff at the Counties-Manukau 
and Otahuhu Police Prosecutions Section, Auckland (Morgan, 2017; Fletcher, 2017) and Road 
Policing at NZ Police National Headquarters (Welsh, 2017), as well as in the Pacific region – 
Vanuatu, Fiji, Tongan and Samoa (Galuvoa, 2018; Grewe, 2018; Kalura, 2018; Mishra, 2018).  




intoxicated although showing no evidence of this in breath screening tests.  Some of these 
drivers were believed to have recently consumed kava, however due to limited knowledge 
regarding kava’s effects on driving, together with no current measurement of impact, officers 
were often prevented from taking decisive action unless other offences had occurred. The 
findings were also discussed with ESR scientists responsible for testing the presence of drugs in 
blood samples (21 April 2017, Polson & McCarthy). They reported an increased detection of 
kava in the blood of motor vehicle accident victims – both survivors and deceased.  However, 
they acknowledged their lack of understanding and applicability regarding these findings. 
 
  
5 Conclusions and recommendations 
The use of kava by Pacific peoples as part of cultural practice and talanoa, and by non-
Pacific people as a social lubricant and alcohol alternative, is increasing.  It is common for kava 
drinkers to consume up to 3.6 litres of kava over prolonged periods of up to six hours (Aporosa, 
2014b).  The effects of kava are described as slightly euphoric although non-hallucinogenic, with 
relaxant anti-anxiety effects similar to Benzodiazepine (Sarris et al., 2013). High consumption of 
kava is observed to produce slower motor response and slurred speech (Morgan, 2014/2017; 
Welsh, 2017). While there are potential benefits from kava drinking and factors making kava a 
better choice than other forms of recreational drugs such as alcohol, (Aporosa & Tomlinson, 
2014), the effects of kava drink on reaction time and divided attention presents some important 
questions that need to be addressed.  
 
This report on an experimental study with a group of practiced kava drinkers, as well as 
non-kava drinkers, while showing some effects, did not reveal a significant reading on reaction 
time and divided attention. Experts suggested frequent interruptions to test participants was a 
possible reason for a lack of test results, implying fewer tests may have produced an alternative 
result. Other factors may have led to the inconclusive results, including ‘reverse tolerance’ 
(Singh, 2004a) and the use of visual-sensory tests. As Bwarenaba et al. (2017) have pointed out, 




neurophysiological mechanisms associated with kavalactone metabolism” (p.5), hence this calls 
for a re-think in how to measure kava consumption and its effects, especially in the case of kava 
drinking and driving. 
 
Although the experimental study did not reveal significant data, the anecdotal evidence 
from police, who continue to apprehend drivers who appear intoxicated while showing negative 
results from breath tests, shows that more work in this field is urgently required. With new 
testing looking in more detail at the central nervous system, to measure impairment as opposed 
to visual response, this may reveal more credible and reliable data. A neuroscientific assessment 
tool, which measure kava affect via the CNS, has shown promise in preliminary tests and has 
been endorsed by a panel of experts as a viable means to continue this important research.  
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